Conjunctivitis as sole symptom of COVID-19: A case report and review of literature

Zeynep Kayaarasi Ozturker

Abstract
Introduction: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a novel virus causing an ongoing pandemic in 2020. Although the symptomatic patients infected by SARS-CoV-2 generally show respiratory distress, atypical manifestations such as conjunctivitis are also observed. A series of cases are reported in which reverse transcriptase polymerase chain reaction (RT-PCR) testing on tears had demonstrated the presence of the virus. However, the transmission of the virus through ocular fluids remains unknown.

Case description: In this case report, the development of conjunctivitis is presented as the sole symptom of a new coronavirus disease 2019 (COVID-19) in an emergency health care worker. The patient’s first application was to the ophthalmology clinic due to redness, stinging, tearing, and photophobia for one day in the right eye. The patient had no symptoms of fever, cough, shortness of breath, or fatigue. Two days later, the RT-PCR test, blood analysis, and chest computed tomography (CT) were applied to the patient for being in contact with a COVID positive patient. Conjunctival swabs did not identify SARS-CoV-2 by RT-PCR. However, nasopharyngeal swab and blood test confirmed the diagnosis of COVID-19. Chest CT did not show pneumonia.

Conclusion: This phenomenon shows that conjunctivitis may occur as a sole manifestation of COVID-19 which needs to be carefully evaluated by health care workers and eye care professionals during the pandemic.

Keywords
Conjunctivitis, COVID-19, novel coronavirus, ocular infection, SARS-CoV-2

Introduction
Coronavirus Disease 2019 (COVID-19) is a highly contagious newly recognized infection that has a significant worldwide impact on mortality and economic morbidity. Initial reports established from respiratory samples revealed severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) as the causative. Generally, patients infected with SARS-CoV-2 develop respiratory illness, with the first symptoms of fever, cough, and fatigue that quickly progress to pneumonia. Several patients were observed with atypical manifestations at the onset of the illness, such as conjunctivitis, or even presented with asymptomatic infection.

SARS-CoV-2 gains entry into host cells by binding to the angiotensin-converting enzyme 2 (ACE-2) receptor, which is distributed among various tissues, including the conjunctiva. During the SARS associated coronavirus outbreak of 2003, a study indicated that healthcare workers suffered from a higher risk of SARS infection when there was unprotected eye contact with secretions. There are increasing reports suggesting that a few COVID-19 pneumonia cases began with conjunctivitis as the initial symptom following contact with confirmed patients. Detection of viral RNA by reverse transcriptase polymerase chain reaction (RT-PCR) can be useful in early detection of SARS-CoV-2 infection and taking appropriate quarantine measures. Therefore, determining whether SARS-CoV-2 is capable of transmitting through contact

Department of Ophthalmology, Baskent University Istanbul Hospital, Istanbul, Turkey

Corresponding author:
Zeynep Kayaarasi Ozturker, Department of Ophthalmology, Baskent University Istanbul Hospital, Altunizade Mah. Kiskili Cad. Oymaci Sok. No: 7, Uskudar, Istanbul 34662, Turkey.
Email: zeynepkayaa@yahoo.com
with conjunctiva is an important consideration that warrants for exploration.

Here, we present a case report of a health care worker diagnosed with COVID-19 who experienced conjunctivitis as the first and sole symptom of the disease. We believe it is essential for healthcare practitioners who play a significant role in the battle against the pandemic, to be knowledgeable about this problem and to take necessary steps to prevent the spread of the disease.

The study followed the tenets of the Declaration of Helsinki. The patient signed written informed consent for the research use of clinical records and data included in the study.

Case description

A 32-year-old otherwise healthy nurse working in the Emergency Department of Baskent University presented to the ophthalmology clinic on May 8, 2020, with one day history of redness, stinging, watery discharge, and photophobia in his right eye. The patient had no symptoms of fever, cough, shortness of breath, or general malaise. In his story, he did not declare any travel abroad in the last 14 days. The patient was diagnosed with idiopathic anterior uveitis in the right eye 2 years ago. Due to the regulations determined by the Turkish Republic Ministry of Health Department, oral and nasopharyngeal swab tests for SARS-CoV-2 were recommended for health care workers on demand. Upon the patient’s request, RT-PCR tests applied on April 14, 2020, and April 24, 2020, had negative results consequently. In his ophthalmic examination, the visual acuity was 20/20 for both eyes without correction. Intraocular pressure was 13 mmHg on the right and 14 mmHg on the left eye. Slit-lamp examination of the right eye revealed eyelid edema and serous secretion with 2+ conjunctival injection, mild chemosis, and follicular reaction in the upper and lower fornices (Figure 1). The cornea was transparent, and no sign of inflammation was detected in the anterior chamber. Fundus examination revealed normal optic disc and macula. Anterior and posterior segment examination of the left eye was normal. Physical examination did not show any tenderness or enlargement of the submandibular, preauricular, or cervical lymph nodes. The patient declared that he wore personal protective equipment during close contact with suspected COVID-19 cases in the Emergency Department, but on some occasions, he had to remove his protective eyewear during the interventions.

Figure 1. A follicular conjunctival reaction in the upper and lower forniceae, serous secretion, and mild chemosis in the right eye of the patient two days before the diagnosis of COVID-19.

Considering acute conjunctivitis, moxifloxacin eye drop QID and artificial tears without preservative QID were prescribed for 7 days. On May 10, 2020, his mother, whom he lives together, developed a cough and fatigue, and RT-PCR test for nasopharyngeal swab was declared positive for COVID-19. Given his direct contact with his mother and occupational exposure, a nasopharyngeal RT-PCR test was applied to him on the same day, and a positive result was reported for SARS-CoV-2. Nasal swabs for Influenza a and b virus antigens were negative. His chest computed tomography and chest X-ray showed no signs of pneumonia (Figure 2). The routine blood examination showed high levels of glucose (114 mg/dL), C-reactive protein (13.00 mg/L), AST (44 U/L), ALT (108 U/L), LDH (251 U/L), and monocytes% (14.5%). He started taking systemic hydroxychloroquine and azithromycin for 5 days and instructed to self-quarantine until the complete resolution of the infection. On day 5 after diagnosis, the patient consulted his ophthalmologist by telemedicine service due to the worsening of his eye symptoms. Because of the infectious nature of COVID-19, quarantine protocols prevented access to the hospital during the active phase of the disease. Owing to the persistence of ocular complaints, the tear, and conjunctival swab samples were acquired by home visit. The samples were collected by conjunctival swab technique under the
patient’s approval. Upper and lower eyelids of both eyes were everted, and two separate samples were obtained by sweeping both fornices with sterile cotton swab without topical anesthesia. The swabs were inserted into a viral transport medium in ice before being tested for SARS-CoV-2. The patient had negative RT-PCR results for eye samples. Routine adenovirus tests also yielded a negative result.

**Conclusion**

Ocular diseases caused by coronaviruses are relatively rare compared to adenovirus and influenza viruses. Although it is known that the main route of transmission of the SARS-CoV-2 is through the respiratory tract, several studies have raised concerns due to infection in the unprotected eyes (Table 1). So far, it has not been clarified whether ocular secretions are contagious.

Based on current literature, SARS-CoV-2 can be detected in the swab samples taken from the conjunctiva by the RT-PCR method. In a study of 30 COVID positive patients, conjunctivitis developed in one patient (3.3%), which was the only symptom during the disease. Conjunctival specimens taken at days 3 and 5 gave positive results for viral RNA in the same patient, whereas all other patients had negative results. Conjunctival secretion of the patient was also tested for Herpes simplex virus, adenovirus, and other common viruses of conjunctivitis. However, the results were all negative indicating that the viral conjunctivitis of the patient might be related to SARS-CoV-2. Another study demonstrated conjunctivitis-like ocular findings in a much larger proportion of cases (31.6%). Conjunctival PCR was found to be positive only in two cases (5.3%). Blood test parameters, including white blood cell, neutrophil, procalcitonin C, C-reactive protein, and lactate dehydrogenase levels, have also been reported to be higher in patients with conjunctivitis. In a similar study, the proportion of positive results for conjunctival SARS-CoV-2 was 2.5% which was significantly lower than the nasopharyngeal SARS-CoV-2 rate. However, it was suggested that a single time point conjunctival sampling might lead to a low rate of virus detection in ocular samples.

The studies demonstrating serial conjunctival swab testing during the disease have shown that SARS-CoV-2 RNA may persist for up to 21 days, even after the virus disappears in the nasal swabs. In addition, the RNA can be re-detected in the conjunctiva after some time, indicating a persistent replication of the virus. The cytopathic effect of the RNA sample after inoculation in the Vero E-6 cell culture was also demonstrated. In contrast, another study suggested that the risk of SARS-CoV-2 transmission through tears was low. Among a total of 17 patients, only one patient had conjunctival injection and chemosis during the stay in the hospital. Conjunctival RT-PCR tests conducted on day three and day 20 were negative for all patients. The virus has been incubated in cell culture, and no cytopathic effect has been determined.

In a separate case study of a 70- year-old man with symptoms of fever, cough, and fatigue, sequential conjunctival RT-PCR results remained positive until around two weeks after the nasopharyngeal RT-PCR results were negative. His left eye had previously been diagnosed with nasolacrimal duct stenosis. In this clinically cured patient, the conjunctival swab of the left eye was still positive, suggesting that the obstruction of the lacrimal drainage system may reduce the virus clear through the eye and provide its shedding persistently.

Five studies have described biomicroscopic findings of COVID-19 patients with conjunctivitis. Ocular symptoms have emerged as the first symptom in all but one of these cases. Ocular complaints have been reported within a spectrum of red eye, watery discharge, photophobia, foreign body sensation, and eyelid edema. Remarkable details in the slit-lamp examination were serous secretion, follicular reaction in the upper and lower eyelid conjunctiva, chemosis, keratoconjunctivitis, and pseudomembranous inflammation. In four of these cases, SARS-CoV-2 viral RNA was detected in the swab samples taken from the conjunctiva.

Conjunctivitis remained the only sign and symptom of four active COVID-19 cases with a history of travel to the Lombardy region in Italy. None had a fever, general malaise, or respiratory symptoms, consistent with our case. This report emphasizes the importance of ocular symptoms which can be overlooked if the patients do not show typical systemic symptoms of the disease.

Studies have shown that SARS-CoV-2 needs ACE-2 receptors for cell invasion.
found not only in human type 2 alveolar epithelial cells but also in the cornea and conjunctiva. This suggests that ocular surface tissue may be a potential target tissue for SARS-CoV-2. Whether ocular contact with SARS-CoV-2 causes COVID-19 disease is unclear. However, according to one proposed theory, when the ocular surface comes into contact with SARS-CoV-2, virus particles can cause infection by draining the respiratory tract through the nasolacrimal canal.

It is not yet known whether SARS-CoV-2 causes a more severe ocular disease beyond keratoconjunctivitis. It has been demonstrated that a murine coronavirus was strongly tropic for retinal cells when introduced by corneal, anterior chamber, intravitreal, and intracerebral routes. Coronavirus was detected in the ganglion cell layer ten days after inoculation, and long-term retinal pigment epithelium fibrosis and retinal atrophy have been detected after 14 weeks. Fibroblasts are suggested to play a significant role in the damaged tissue leading to gliosis of the retinal pigment epithelium.

Serious eye problems may not be adequately assessed in patients with high SARS-CoV-2 virus loads who are often treated in intensive care units for vital reasons. One report demonstrated severe ocular symptoms including tarsal hemorrhage, petechia and pseudomembranes in a 63-years-old patient who required intensive care surveillance and ventilatory support. Collected swabs did not identify any bacterial or viral etiology in conjunctival secretions and tears. While signs of conjunctivitis have usually been reported in adult patients, there has been one report on infected children. A 2-years-old asymptomatic boy was detected through community screening with positive results of oropharyngeal SARS-CoV-2 RNA. He developed conjunctivitis and eyelid dermatitis on day seven, which gradually disappeared in 5 days. As conjunctival swab was not taken, it is not clear whether a virus or secondary bacterial infection caused ocular symptoms.

Telemedicine services also helped detect cases of conjunctivitis in the COVID-19 lockdown. One study reported a 27-years-old male patient who used telemedicine due to redness and foreign body sensation in his left eye. Examination revealed lid edema and conjunctival hyperemia which required treatment. After 12 h, he admitted to

### Table 1. Demographics and Clinical Data of COVID-19 Patients with Conjunctivitis.

| Studies                | Country     | F/M   | Age (years) | Conjunctivitis as Initial or Corresponding Symptom | Time and Result of cPCR after COVID Diagnosis (Days) |
|------------------------|-------------|-------|-------------|---------------------------------------------------|--------------------------------------------------|
| **Case reports**       |             |       |             |                                                   |                                                  |
| Zhang et al.13         | China       | F     | 29          | Corresponding                                     | 6 (+)                                            |
| Chen et al.10          | China       | M     | 30          | Corresponding                                     | 14 (+), 17 (+), 19 (−)                            |
| Cheema et al.11        | Canada      | F     | 29          | Initial                                           | 5 (+)                                            |
| Hu et al.9             | China       | NA    | 70          | Corresponding                                     | 25 (+), 29 (+), 31 (+), 32 (+), 36 (+), 39 (−)   |
| Colavita et al.7       | Italy       | F     | 65          | Initial                                           | 3 (+), 9 (+), 13 (+), 17 (+), 21 (−)             |
| Khavandi et al.12      | Iran        | M     | 65          | Initial                                           | NA                                               |
| Salducci and La Torre14| Diamond Princess | M | 72          | Initial                                           | NA                                               |
| Navel et al.20         | France      | M     | 63          | None                                              | 20 (−)                                           |
| Daruich et al.22       | Argentina   | M     | 27          | Initial                                           | NA                                               |
| Wu et al.21            | China       | M     | 2           | Initial                                           | NA                                               |
| Ya et al.25            | China       | 1/2   | Range: 16–67| 2 initial                                         | NA                                               |
| Scalinci and Battagliola15 | Italy       | 1/4   | Range: 41–65| All initial                                       | NA                                               |
| **Cohort studies**     |             |       |             |                                                   |                                                  |
| Xia et al.4            | China       | 9/21  | Mean 54.5   | 1/30 initial                                      | 7.3 ± 3.8 [1/30 (+)]                             |
| Chen et al.23          | China       | 271/263 | Median 40–50| 3/5 initial                                      | NA                                               |
| Seah and Agrawal8      | Singapore   | 6/11  | Median 37   | 1/17 corresponding                                | 3–20 [all patients (−)]                         |
| Hong et al.24          | China       | 25/31 | Mean 48     | 6/56 corresponding                                 | 7.3 ± 3.8 [1/56 (+)]                             |
| Wu et al.5             | China       | 13/25 | Mean 65.5   | 1/38 corresponding                                 | NA [2/28 (+)]                                    |
| Zhou et al.6           | China       | 68/53 | Median 48   | 8/121 corresponding                                | NA [3/121 (+)]                                   |

F: female; M: male; cPCR: conjunctival swab polymerase chain reaction; SD: standard deviation; NA: non-applicable.
the hospital because of added complaints of fever, cough, and dyspnea. In two other studies, ocular findings were evaluated retrospectively by making phone calls with the patients, and it was concluded that ocular symptoms were common in COVID-19 patients which might have clinical diagnostic significance.23,24

Recently, positive RT-PCR test findings in conjunctival swab samples of confirmed COVID-19 patients provide objective evidence for SARS-CoV-2 ocular surface infection. However, there are also patients with positive conjunctival RT-PCR results with no evidence of conjunctivitis.25 Therefore, the relationship between ocular surface infection and COVID-19 and whether the disease can be transmitted through the ocular surface needs further research.

In conclusion conjunctivitis may appear to be the only sign and symptom of COVID-19, and these patients may not have fever, fatigue, or respiratory symptoms that may cause suspicion. The patients are generally those who report contact with COVID positive patients and therefore undergo nasopharyngeal RT-PCR tests. According to a recent report, one-third of eye care professionals involved in the diagnosis and treatment of the patients during the pandemic accidentally acquired COVID-19 and demonstrated severe disease, including death.26 Thus, all physicians and ophthalmologists should be cautious when addressing a patient with conjunctivitis, and adopt proper steps for the possible ocular transmission of SARS-CoV-2 until a vaccine is available. The RT-PCR test for nasopharyngeal or conjunctival swabs may help in early diagnosis of the disease if patients have no symptoms other than conjunctivitis.

Acknowledgements
I thank Biologist Gulen Varan Ucak for her assistance in collecting nasopharyngeal and conjunctival swab samples for the RT-PCR analysis.

Declaration of competing interests
The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

Funding
The author(s) received no financial support for the research, authorship, and/or publication of this article.

Informed consent statement
This case report was written using the clinical data of the patient in 2020. General consent was obtained in which the patient agrees with the research use of residual body parts and clinical records and data with anonymization.

ORCID iD
Zeynep Kayaarasi Ozturker https://orcid.org/0000-0002-5513-9857

References
1. Wan Y, Shang J, Graham R, et al. Receptor Recognition by the Novel Coronavirus from Wuhan: An Analysis Based on Decade-Long Structural Studies of SARS Coronavirus. J Virol. 2020; 94(7): e00127-20.
2. Raboud J, Shigayeva A, McGeer A, et al. Risk factors for SARS transmission from patients requiring intubation: A multicentre investigation 221 in Toronto, Canada. PLoS ONE 2010; 5: e10717.
3. Belser JA, Rota PA and Tumpey TM. Ocular tropism of respiratory viruses. Microbirt Mol Biol Rev. (2013) 77: 144-56.
4. Xia J, Tong J, Liu M, Shen Y and Guo D. Evaluation of coronavirus in tears and conjunctival secrections in patients with SARS-CoV-2 infection [published online ahead of print, 2020 Feb 26]. J M. Virol. 2020;
5. Wu P, Duan F, Luo C et al. Characteristics of Ocular Findings of Patients with Coronavirus Disease 2019 (COVID-19) in Hubei Province, China. JAMA Ophthalmol. 2020;138(5): 5513-9857.
6. Zhou Y, Duan C, Zeng Y, et al. Ocular Findings and Propagation with Conjunctival SARS-COV-2 in COVID-19 Patients. Ophthalmol. 2020; S0161-6420 (20) 30405-X.
7. Colavita F, Lapa D and Carletti E, et al. SARS-CoV-2 isolation from conjunctival secretions of a patient with COVID-19 in Italy with prolonged viral RNA detection. Ann. Intern. Med. 2020.
8. Saravanan and Agrawal R. Can the Coronavirus Disease 2019 (COVID-19) Affect the Eyes? A Review of Coronavirus and Ocular Implications in Humans and Animals. Ocul Immunol Inflamm. 2020; 28(3): 391-395.
9. Hu Y, Chen T, Liu M, et al. Positive detection of SARS-CoV-2 combined HSV1 and HHV6B virus nucleic acid in tear and conjunctival secretions of a non-conjunctivitis COVID-19 patient with obstruction of common lacrimal duct [published online ahead of print, 2020 May 14]. Acta Ophthalmol.
10. Chen L, Liu M and Zhang Z, et al. Ocular manifestations of a hospitalised patient with confirmed 2019 novel coronavirus disease. Br J Ophthalmol. 2020;104 (6): 748-751.
11. Cheema M, Aghazadeh H and Nazarali S, et al. Keratoconjunctivitis as the initial medical presentation of the novel coronavirus disease 2019 (COVID-19) [published online ahead of print, 2020 Apr 2]. Can J Ophthalmol. 2020; S0008-4182 (20) 30305-7.
12. Khavandi S, Tabibzadeh E, Naderan M and Shoar S. Corona virus disease-19 (COVID-19) presenting as conjunctivitis: atypically high-risk during a pandemic [published online ahead of print, 2020 Apr 27]. Cont Lens Anterior Eye. 2020; S1367-0484 (20) 30083-7.
13. Zhang X, Chen X, Chen L, et al. The evidence of SARS-CoV-2 infection on ocular surface. Ocul Surf. 2020; 18(3): 360-362.
14. Salducci M and La Torre G (2020). COVID-19 emergency in the cruise’s ship: A case report of conjunctivitis. La Clinica Terapeutica. 2020; 171(3), e189-e191.
15. Scalinci SZ and Trovato Battagliola E. Conjunctivitis can be the only presenting sign and symptom of COVID-19. IDCases. 2020; 20: e00774.
16. Zou X, Chen K and Zou J, et al. Single-cell RNA-seq data analysis on the receptor ACE2 expression reveals the potential risk of different human organs vulnerable to 2019-nCoV infection. Front Med. 2020;14(2):185-192.
17. Robbins SG, Detrick B and Hooks JJ. Retinopathy following intravitreal injection of mice with MHV strain JHM. *Adv Exp Med Biol.* 1990; 276: 519–524.

18. Robbins SG, Detrick B and Hooks JJ. Ocular tropisms of murine coronavirus (strain JHM) after inoculation by various routes. *Invest Ophthalmol Vis Sci.* 1991; 32(6): 1883–1893.

19. Neri P and Pichi F. COVID-19 and the eye immunity: Lesson learned from the past and possible new therapeutic insights. *Int Ophthalmol.* 2020; 40(5): 1057-1060.

20. Navel V, Chiambaretta F and Dutheil F. Haemorrhagic conjunctivitis with pseudomembranous related to SARS-CoV-2 [published online ahead of print, 2020 May 6]. *Am J Ophthalmol Case Rep.* 2020; 100735.

21. Wu P, Liang L, Chen C, et al. A child confirmed COVID-19 with only symptoms of conjunctivitis and eyelid dermatitis [published online ahead of print, 2020 Apr 24]. *Graefes Arch Clin Exp Ophthalmol.* 2020; 1-2.

22. Daruich A, Martin D and Bremond-Gignac D. Ocular manifestation as first sign of Coronavirus Disease 2019 (COVID-19): Interest of telemedicine during the pandemic context. *J Fr Ophtalmol.* 2020; 43(5): 389-391.

23. Chen L, Deng C and Chen X, et al. Ocular manifestations and clinical characteristics of 534 cases of COVID-19 in China: A cross-sectional study. *medRxiv [Preprint].* 2020 March 16. doi:10.1101/2020.03.12.20034678.

24. Hong N, Yu W and Xia J, et al. Evaluation of ocular symptoms and tropism of SARS-CoV-2 in patients confirmed with COVID-19 [published online ahead of print, 2020 Apr 26]. *Acta Ophthalmol.* 2020; 10.1111/aos.14445.

25. Ya Y, Yanping S and Ming Y, et al. Novel coronavirus pneumonia combined with conjunctivitis: Three case report. Zhonghua Shiyan Yanke Zazhi/Chinese Journal of Experimental Ophthalmology. 38. 242-244. 10.3760/cma.j.issn.2095-0160.2020.0006.

26. Qiao C, Zhang H, He M, et al. Symptomatic COVID-19 in Eye Professionals in Wuhan, China [published online ahead of print, 2020 Apr 18]. *Ophthalmology.* 2020; S0161-6420 (20) 30403-6.